CJC-1295 (without DAC), also known as CJC-1295 (No DAC), is a synthetic growth hormone-releasing hormone (GHRH) analog with a half-life of approximately 30 minutes. Unlike the DAC version, this peptide does not contain a maleimidoproprionic acid modification — it produces acute, pulsatile GH release that closely mirrors the natural physiological secretion pattern of endogenous GHRH.

The peptide consists of a modified 30-amino acid GHRH(1-29) sequence with D-Ala at position 2 (for DPP-IV resistance), Gln at position 8, Ala at position 15, and Leu at position 27. These substitutions collectively enhance stability and receptor affinity compared to native GHRH, without the extended albumin-binding half-life of the DAC variant.

Research with CJC-1295 (without DAC) has focused on its ability to stimulate pulsatile GH and IGF-1 elevation in acute dosing protocols. Its shorter half-life makes it well-suited for studies requiring precise timing of GH pulses, and it is frequently studied in combination with Ipamorelin for synergistic GH secretagogue effects.

Research Applications:

• Long-acting GHRH receptor stimulation studies
• Sustained GH and IGF-1 elevation research protocols
• Protein synthesis and anabolic pathway investigations
• Lipolysis and body composition research in animal models
• Comparison of GHRH analogs with different half-lives
• Chronic dosing protocols in rodent research models

Key Specifications:

• Purity: 99.12% verified by Freedom Diagnostics testing
• Dosage: 5mg per vial
• Category: Growth Hormone
• Storage: -20°C or colder (lyophilized)
• Stability: Up to 2 years when stored properly

Research Highlights:

• 99.12% purity verified by Freedom Diagnostics HPLC analysis
• Short ~30-minute half-life produces acute, pulsatile GH release
• Sustained GH and IGF-1 elevation from single administration
• Maintains physiological pulsatile GH secretion patterns
• Molecular weight: 3,647.2 Da | CAS: 863288-34-0 | PubChem CID: 91971820